NCT05451303 Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
| NCT ID | NCT05451303 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Viome |
| Condition | Oral Squamous Cell Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 475 participants |
| Start Date | 2022-05-27 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 475 participants in total. It began in 2022-05-27 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis. This study will recruit only at existing clinical sites and will NOT use any additional clinical sites.
Eligibility Criteria
Inclusion Criteria * Signed Informed Consent obtained * 18 years and older * At a high risk of developing oral or throat cancer based on clinician's discretion Exclusion Criteria * Pregnancy * Use of fertility enhancing medications
Contact & Investigator
Cristina Julian, PhD
PRINCIPAL INVESTIGATOR
Viome
Frequently Asked Questions
Who can join the NCT05451303 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Oral Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05451303 currently recruiting?
Yes, NCT05451303 is actively recruiting participants. Contact the research team at studies@viome.com for enrollment information.
Where is the NCT05451303 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05451303 clinical trial?
NCT05451303 is sponsored by Viome. The principal investigator is Cristina Julian, PhD at Viome. The trial plans to enroll 475 participants.